These favorable effects of antiandrogenic treatments on metabolic and body weight regulation systems have been reproduced in an animal PCOS model; for example, administration of flutamide reduces body weight and adipocyte size in a letrozole-induced PCOS mice model (produced using an aromatase inhibitor), concomitantly with the attenuation of hyperandrogenemia and restoration of the estrous cycle [41]. Here, CYP19A1 is linked to polycystic ovary syndrome.